SOUTH SAN FRANCISCO, CA – Abdera Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable precision radiopharmaceuticals for cancer, announced that initial… Read More
Gilgamesh’s lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). Bretisilocin is a novel, short-acting serotonin… Read More
All 2025 pre-filled syringe doses for the Canadian market to be made in Canada, marking a domestic production milestone CAMBRIDGE, MA – Moderna, Inc. (NASDAQ:MRNA) announced that Health Canada has… Read More
DLBCL is an aggressive cancer with a high risk of progression meaning urgent and effective treatments are needed for people who relapse or have refractory disease This Columvi regimen offers… Read More
Eligible Canadian patients with heterozygous familial hypercholesterolemia (HeFH) are one step closer to publicly funded access to cholesterol lowering treatment. MONTRÉAL, QC – Novartis Pharmaceuticals Canada Inc. is pleased to… Read More
